^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CDX-585
i
Other names: CDX-585, BSI-585, BSI 585, CDX 585, BSI585, CDX585
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Biosion, Celldex
Drug class:
PD1 inhibitor, ILT-4 inhibitor
Related drugs:
13d
A Study of CDX-585 in Patients With Advanced Malignancies (clinicaltrials.gov)
P1, N=130, Active, not recruiting, Celldex Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> May 2025 | Trial primary completion date: Dec 2024 --> May 2025
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
CDX-585
over1year
A Study of CDX-585 in Patients With Advanced Malignancies (clinicaltrials.gov)
P1, N=130, Recruiting, Celldex Therapeutics | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
CDX-585
almost2years
CDX-585, a novel bispecific antibody targeting PD-1 and ILT4 (AACR 2023)
(2022 Clin Cancer Res 28: 57-70) reported encouraging results of the initial clinical study combining the ILT4 antagonist mAb MK-4830 with pembrolizumab. Doses of CDX-585 up to 60 mg/kg were well tolerated in cynomolgus macaques and displayed a favorable pharmacokinetic profile. Together these data demonstrate that CDX-585 effectively combines PD-1 and ILT4 blockade into one molecule with favorable biophysical and functional characteristics supporting the initiation of a dose-escalation clinical trial in patients with advanced solid tumors.
PD(L)-1 Biomarker • IO biomarker
|
CD40 (CD40 Molecule)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • CDX-585 • MK-4830
Share via
